Permanent neonatal diabetes was previously assumed to require insulin injection or infusion for life. Recently, permanent neonatal diabetes resulting from mutations in the two protein subunits of the adenosine triphosphatesensitive potassium channel (Kir6.2 and SUR1) has proven to be successfully treatable with high doses of sulfonylureas rather than insulin. Many patients with these mutations first develop hyperglycemia in the nursery or intensive care unit. The awareness of the neonatolgist of this entity can have dramatic effects on the long-term care and quality of life of these patients and their families. In this study, we present the experience of our center, highlighting aspects relevant to neonatal diagnosis and treatment.
Introduction
Permanent neonatal diabetes is persistent, insulin-requiring hyperglycemia presenting within the first 6 months of life. [1] [2] [3] [4] [5] The incidence has been estimated to range from 1 in 89 000 to 1 in 260 000 live births. The most common cause is heterozygous activating mutations in the gene KCNJ11, which encodes the Kir6.2 subunit of the adenosine triphosphate-sensitive potassium channel. Clinical presentation is usually that of severe hyperglycemia or ketoacidosis, but failure to thrive in the first few months of life can be the main presenting feature in some patients. Many patients with mutations in the KCNJ11 gene can be switched from insulin therapy to high doses of sulfonylureas with better diabetes control and improved quality of life. 2, [6] [7] [8] A diagnosis of monogenic diabetes caused by a mutation in KCNJ11 should be considered in the following cases: (1) diabetes diagnosed within the first 6 months of life, (2) infants born small for gestational age and diagnosed with diabetes, 3 (3) infants with diabetes and negative testing for type 1 diabetes-associated antibodies and (4) family history of diabetes diagnosed before 6 months of age. To our knowledge, the first case in the United States of sulfonylureatreated diabetes caused by a mutation in KCNJ11 was diagnosed at our center (Table 1 , patient 6). 1, 5 Monogenic diabetes, caused by mutations in key components of insulin secretion, is often misdiagnosed as type 1 or type 2 diabetes. Therefore, all patients diagnosed with diabetes before 6 months of age should undergo genetic testing for correct categorization of diabetes and its recurrence risk 9 as well as optimization of treatment and maximizing the chance of insulin independence.
Methods
Data were collected retrospectively by chart review of patients diagnosed with diabetes before 6 months of age, and found to have a mutation associated with diabetes while receiving diabetes care at the Pediatric Diabetes Center, Loma Linda University. Testing for diabetes autoimmune antibodies (islet cell, glutamic acid decarboxylase and insulin) was carried out at the time of diabetes diagnosis, other testing was concomitant with mutation detection.
Results
Eight patients had permanent neonatal diabetes and a mutation in KCNJ11. In addition, one patient had a mutation in the insulin gene, and another patient (with diabetes, renal cysts and kidney failure) had a mutation in the gene encoding the transcription factor hepatocyte nuclear factor-1b. 10 Only patients with KCNJ11 mutations are presented in this review, which focuses on their clinical presentation and treatment course. These patients are briefly described below and summarized in Table 1 .
Case

Patient 1
Patient 1 is a 20-year-old female diagnosed with type 1 diabetes at the age of 9 weeks. She was born full term, but notably small for gestational age (Table 1) . She presented with ketoacidosis, had been on insulin treatment for 20 years and was using an insulin pump up to the time of genetic testing. She has no family history of diabetes. Mild developmental delay had been noted throughout her life. Genetic testing showed that she was heterozygous for the KCNJ11 mutation R201C. Identification of this mutation allowed insulin to be weaned and discontinued over 11 months with incremental increases in the dose of an oral sulfonylurea agent (glyburide).
Patient 2
Patient 2 is a 9-month-old female, who was admitted to the neonatal intensive care unit at the age of 8 days because of the hyperglycemia detected on screening in view of maternal diabetes. She was born full term, with birth weight and length below average for age (Table 1) . She was presumed to have type 1 diabetes and started on an intravenous insulin drip, then subcutaneous basal bolus insulin therapy. A family history was notable for her mother having early-onset type 1 diabetes. Mutation analysis of the KCNJ11 gene was undertaken after endocrinology consultation, and the patient was found to be heterozygous for the missense mutation R201H. Her mother was subsequently tested and found to have the same mutation (patient 3 below). The patient was started on oral glyburide, (1.25 mg b.i.d) crushed and diluted in 2.5 ml water, and insulin was weaned with incremental increases of glyburide every 2 weeks.
Patient 3
Patient 3 was diagnosed with type 1 diabetes at 4 months of age when she presented with ketoacidosis. She remained on insulin treatment for 17 years. When her daughter (patient 2) was diagnosed with diabetes at the age of 8 days, DNA testing was performed. Genetic testing identified the same mutation (R201H) as her daughter. This patient, currently 18 years of age, has not been started on oral agents yet due to repeated teen pregnancies and poor compliance.
Patient 4
Hyperglycemia was detected in this male infant shortly after birth following glucosuria on routine urinalysis in the nursery, and insulin treatment was started. He was a term small for gestational age baby. Genetic testing showed him to be heterozygous for a novel missense mutation (N48I) in KCNJ11. He was successfully weaned off insulin and has maintained normal glucose without any medications at his current age of 20 months.
Patient 5
This 13-year-old-female was first diagnosed with type 1 diabetes at 6 weeks of age when she presented with ketoacidosis and was started on insulin injections. At the age of 2 years, the patient developed both ataxic and right hemiplegic cerebral palsy, generalized encephalopathy, expressive language delay and motor delay. She has been cared for by her grandparents ever since. At 11 years of age, genetic testing was performed and she was found to have the mutation V59M. The grandparents refused any change in treatment for over a year for fear of new side effects, and only recently agreed to start oral agents. At present, this patient is being switched from insulin to glyburide with a current dose of glyburide of 1 mg kg À1 per day, and once-a-day basal insulin of 0.2 U kg À1 .
Patients 6 and 7
Patient 6 was a full term small for gestational age female baby. She was diagnosed with 'type 1' diabetes at 2 weeks of age and started on insulin injections. Testing for diabetes-related mutations at 7 years of age revealed a mutation (R201H) in KCNJ11, which was subsequently reported to cause sulfonylurea-treatable diabetes. 1, 5 The mother, who had a history of diabetes since infancy, was found to have the same mutation. Patient 6 was successfully transitioned from insulin to glyburide. Ongoing attempts at modifying treatment in the mother are hampered because of her being an adult recipient of public aid.
Patient 8
Patient 3 above recently delivered a second small for gestational age female infant (patient 8) who was tested at 1 month of age for the R201H mutation present in her mother and sister. She was asymptomatic at the time of genetic testing although her initial blood glucose was 14.6 mmol l À1 (300 mg dl
À1
). Testing for diabetes autoimmune antibodies was negative. She was started on glyburide treatment without intervening insulin therapy, and her blood glucose remains adequately controlled to date (age 2 months).
Discussion
The relatively new entity of permanent neonatal diabetes due to activating mutations in the gene KCNJ11 is of particular relevance to practicing neonatologists. Although KCNJ11 mutations are not the only cause of permanent neonatal diabetes, they are the most frequent, and account for 31% of cases in one series. 3 These mutations impair the function of the adenosine triphosphatesensitive potassium channel preventing its physiological closure in response to glucose metabolism. Consequently, the pancreatic b cells cannot secrete insulin in response to glucose. Resultant hyperglycemia mimics that of type 1 (insulin dependent) diabetes in its presentation with severe hyperglycemia, ketoacidosis or failure to thrive. However, high doses of sulfonylurea agents can close the mutant adenosine triphosphate-sensitive potassium channel and allow insulin secretion, presumably in response to incretins. Many patients with permanent neonatal diabetes can be successfully switched from insulin injections to sulfonylurea therapy. This can be carried out over a few days in the inpatient setting or a few weeks for patients at home. 1 In our experience, weekly increments of 25% increase in sulfonylurea dose and decrease in insulin dosages are well tolerated. A decrease in bolus insulin therapy usually precedes weaning basal insulin dosing. Insulin independence is more achievable if sulfonylureas are introduced at a younger age. 3 The diagnosis of neonatal diabetes is often first made in the nursery or neonatal intensive care unit. Thus, the onus is on neonatologists to initiate appropriate referrals and genetic testing. As noted with patient 8, oral agents can be started as soon as a genetic diagnosis is established. The majority of mutations in KCNJ11 are de novo in origin, and the parents do not have permanent neonatal diabetes. DNA testing is indicated in parents with diabetes and encouraged in unaffected parents. Genetic testing for KCNJ11 mutations is available through Clinical Laboratory Improvement Amendments-certified laboratories in the United States and similar laboratories in Europe. Information regarding genetic testing laboratories can be found at Gene Tests (http:// www.ncbi.nlm.nih.gov/sites/GeneTests/lab/clinical_disease_id/ 293343?db¼genetests). In most instances, the health insurance of the patients will cover the cost of genetic testing. Moreover, all parents of patients with KCNJ11 mutations should be offered genetic counseling.
Neonatologists can have a crucial role in the timely testing of infants for monogenic diabetes based on family history, low birth weight and length percentiles, and early hyperglycemia. Some of our patients were diagnosed with KCNJ11 mutations despite marginally positive diabetes auto-antibodies, which may be maternally transmitted, hence positive antibody testing need not exclude patients from screening. Moreover, it is likely that many insulin-dependent adults with diabetes have a mutation in KCNJ11 and the potential of partial or complete insulin independence. This offers an opportunity for both neonatologists and obstetricians to work with diabetologists toward optimum categorization and counseling regarding diabetes in patients and their families. Insulin independence in newborns and infants with diabetes S Shahawy et al
